News

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on whether the timing and combination of certain therapeutics may impact the long-term care for patients with tuberous sclerosis complex. [WATCH TIME: 3 minutes]

PIRA was associated with, for most patients, a sustained accumulation of disability, which was strongly associated with unfavorable long-term outcomes.

Despite previous data suggesting no link, the CDC and FDA will continue to review all evidence for possible increased risk of ischemic stroke.

Glymphatic function demonstrated no significant difference in patients with type 1 and type 2 narcolepsy in comparison with healthy controls.

The neuropsychologist at Rutgers University, in New Brunswick, New Jersey, spoke about her most recent published study on assessing keystrokes on a smartphone in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.

The director of the Headache Center at Allegheny Health Network discussed whole-body therapeutic approaches to chronic migraine, and the difficulties with finding an effective, long-term strategy. [WATCH TIME: 8 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Patients who had higher baseline REM without atonia levels were associated with the largest treatment effects on RSWA with a single 50 mg dose of ulotaront.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending January 14, 2022. [WATCH TIME: 4 minutes]

Sharon Cohen, MD, FRCPC, offered her insight on the significance of the lecanemab approval and what it means for patients with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.

Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.

The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of Alzheimer disease and initiating treatment early when needed. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sarah Boyce. [LISTEN TIME: 21 minutes]

In preclinical animal models, NRL-1049 showed an ability to decrease ROCK-2 activation, a pathway that is hyperactivated in patients with cerebral cavernous malformations.

The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital shared the current research on rapid eye movement in sleep and seizures. [WATCH TIME: 3 minutes]

The trial found no evidence of any clinically relevant benefit from the CHESS intervention across multiple outcomes at multiple time points, nor in any sensitivity or subgroup analyses.

The neurosurgeon at Allegheny Health Network provided background on a new, state-of-the-art tool designed to ultimately improve neurosurgical procedures. [WATCH TIME: 3 minutes]

DaxibotulinumtoxinA, the first and only peptide formulated neuromodulator, has been shown to be safe and well tolerated in doses of 125 and 250 units, with clinically meaningful effect observed by both patients and clinicians.

Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]

The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

The scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai, spoke about a talk given at the 2022 AES conference on seizures after ischemic. [WATCH TIME: 5 minutes]

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.